The inducible costimulator (ICOS),
T cells further suggest that Fyn and NFATc2 act in a common axis, separate from that involving ERK, to drive ICOS transcription. Taken together, our findings indicate that Fyn-calcineurin-NFATc2 and MEK2-ERK1/2 are two independent signaling pathways that cooperate to control TCR-mediated ICOS induction.
T lymphocytes require two signals to be fully activated. The first, an antigen-specific signal, is delivered via the T cell receptor (TCR), while the second, a costimulation signal, is sent mainly via a member of the CD28 family of molecules found on the surface of T cells (1, 2) . The costimulation signal is critical in maintaining the full activation status of antigenstimulated T cells by sustaining their cellular proliferation and differentiation, thus preventing onset of anergy and induction of apoptosis.
The CD28 family of molecules are type I transmembrane glycoproteins and possess putative SH2-and SH3-motifs in their cytoplasmic tails for signal transduction. The prototypic member, CD28, is expressed constitutively on naïve T cells and engaged by the B7-1 (CD80) and B7-2 (CD86) molecules on antigen-presenting cells (APCs) such as macrophages, B cells and dendritic cells. Cognate interaction between CD28 and B7-1 and B7-2 ligands will lead to IL-2 transcription (3), expression of CD25 (IL-2Rα) and entry into cell cycle, as well as induced expression of the cell survival protein Bcl-XB L B in T cells (4) . Another CD28 family member, CTLA-4, acts as a negative regulator in this co-stimulatory pathway by competing for binding to the same B7 ligands and thereby inhibiting IL-2 synthesis and cell cycle progression and thus, terminating T cell responses (2) .
Although CD28 is the predominant costimulatory molecule, it does not account for all costimulatory functions in T cells. Mice lacking CD28 are still able to mount effective responses to some viruses (5) . Furthermore, the production of effector cytokines such as IFN-γ and IL-4 can still be stimulated to normal levels by APCs lacking B7 ligands (6) . In contrast to naïve T cells, the reactivation of antigenexperienced T cells also appears to be less dependent on CD28/B7 interaction (7, 8) . These results suggest that other costimulatory molecules can compensate for the lack of CD28 signaling.
One candidate is the recently discovered inducible costimulator (ICOS), which is also a member of the CD28 family of receptors.
ICOS shares 30% to 40% sequence similarity to CD28 and CTLA-4 but does not have the conserved extracellular MYPPPY motif necessary for binding B7-1 and B7-2 (9, 10). Instead, it binds a different cell surface molecule known as ICOS ligand (ICOSL, also termed B7h, B7RP-1, GL-50, LICOS or B7-H2) that is expressed constitutively on B cells and at low levels on monocytes and whose expression can be induced in fibroblasts, nonlymphoid tissues and other non-professional APCs (11, 12) . ICOS is expressed in both CD4P + P and CD8P + P T cells and may play a more important role in costimulating effector and memory T cells as compared to naïve T cells (13) . ICOS engagement in vitro can contribute to the production of cytokines such as IFN-γ, TNF-α, IL-4, IL-5, and IL-10, but little IL-2 (9, 12, 14) . Recent studies also indicate that in the absence of CD28, ICOS appears to assume the major T cell costimulatory role for humoral immune responses (15) .
Characterization of ICOS-deficient mice revealed that the absence of ICOS impaired humoral immune responses by affecting germinal centre (GC) formation and B cell immunoglobulin class switching (16) (17) (18) (19) . Consistent with a pivotal role for ICOS in GC development, ICOS has been implicated in the maintenance of CXCR5P + P follicular B helper T cells in vivo (20) . Human ICOS deficiency, on the other hand, results in a clinical phenotype indistinguishable from that of adult-onset common variable immunodeficiency (CVID) (21, 22) . The importance of ICOS/ICOSL in costimulating immune reactions can be glimpsed from various murine disease models. In the examples of experimental autoimmune encephalomyelitis (EAE) and cardiac allograft transplantation, ICOS blockade could respectively abrogate immunopathogenesis or prolong allograft survival (23, 24) . Moreover, interference of the ICOS-ICOSL pathway has also been shown to result in the resolution of mercury-induced autoimmunity (25). Last, but not least, ICOS/ICOSL interactions have also been implicated in Th2-mediated allergic diseases such as airway hypersensitivity (26) , allergy and asthma (27) , and acute or chronic graft-versus-host disease (GVHD) (28) .
Despite extensive studies pointing to a crucial role for ICOS in cellular and humoral immunity, little is known about the regulation of ICOS expression. ICOS is absent or expressed at low levels on naïve T cells and is rapidly upregulated upon T cell activation (19, 29) . It is envisaged that the ability to enhance ICOS expression at the appropriate time could lead to more effective immune responses against pathogens. Conversely, the ability to downregulate ICOS expression could modulate the rejection of organ and tissue transplantation and alleviate the severity of autoimmune diseases. Hence, in the present study, we elucidated the signaling pathways originating from TCR and CD28 costimulation that lead to ICOS induction as well as delineate the cis-acting regulatory region and trans-acting transcription factors (TFs) that govern ICOS transcription. We found that the Fyn-calcineurin-NFATc2 and MEK2-ERK1/2 signaling pathways operate independently but converge on the icos core promoter to induce ICOS transcription. mice were purchased from The Jackson Laboratory. All mice were bred and used between 8 to 12 weeks of age according to institutional guidelines. Murine EL4 thymoma cell line was maintained in complete RPMI 1640 medium supplemented with 10% fetal calf serum (HyClone, Logan, UT), 2 mM L-glutamine, 50 mg/ml penicillin, 50 mg/ml streptomycin, 100 mM HEPES and 55 μM β-mercaptoethanol.
EXPERIMENTAL PROCEDURES
Anti-CD3 (145-2C11) and anti-CD28 (37.51) antibodies for cell stimulation, FITC-conjugated anti-CD4 (GK1.5), anti-CD8 (53-6.7) and biotinconjugated anti-ICOS (7E.17G9) antibodies and PE-Cy5-conjugated streptavidin for flow cytometric staining were obtained from BD Pharmingen (San Diego, CA). Chemical inhibitors FK506 (10 μM), CsA (low dose: 5 ng/ml; high dose: 50 ng/ml), wortmannin (WM) (100 nM) and rapamycin (RAPA) (10 nM) were obtained from Sigma-Aldrich (St Louis, MO). PP2 (5 μM), damnacanthal (100 nM), piceatannol (50 μM), SB203580 (10 μM), JNK inhibitor I (5 μM) and NF-κB competitor peptide SN50 (10 μM) were purchased from Calbiochem (San Diego, CA). U0126 (50 μM) were treated with anti-CD3 and anti-CD28 mAbs for 16 h, crosslinked with 1% formaldehyde for 10 min at 37°C, washed with ice-cold PBS containing 1 mM PMSF, harvested and lysed in SDS buffer. DNA was sheared by ultrasonication using a High Intensity Ultrasonic Processor (Heat Systems) for 8 × 12 s pulses at 30% amplitude. Lysates were centrifugated, resuspended in ChIP dilution buffer and pre-cleared using salmon sperm DNA/protein A-agarose. Protein-DNA complexes were immunoprecipitated with 6 μg of anti-NFATc2 or isotype-matched control Ab (mouse IgG2a) overnight at 4°C. Ab-protein-DNA complexes were then captured using salmon sperm DNA/protein A-agarose for 1 h at 4°C. After washing beads with low and high salt, LiCl and TE buffers, the protein/DNA complexes were eluted using 1% SDS, 0.1 M NaHCOB 3 B buffer and disrupted by heating at 65°C for 4 h. DNA was then phenol/chloroformextracted and ethanol-precipitated and subjected to PCR using primers spanning −288 to TSS of icos promoter: sense 5′-CCG CTC GAG CAT GCA TGC ATC CAT C-3′; antisense 5′-CCC AAG CTT AGT GCT CAA AAG TGT CAG-3′ (94°C, 15 s; 60°C, 30 s; 72°C, 1 min, 28 cycles). PCR products were then separated on 2% agarose gels. Electrophoretic mobility shift assay (EMSA) -Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce Biotechnology, Rockford, IL). Briefly, cells (10×10P were untreated or stimulated for 16 h and washed in PBS at 4°C. Nuclear extracts were prepared by hypotonic lysis and high salt extraction, and subsequently cleared of insoluble material by centrifugation at 13,000 rpm for 5 min at 4 °C before being concentrated with a microcon-3 column (Millipore Corp., Billerica, MA). Nuclear extracts were stored at −80°C prior to use, and protein content measured using Bradford assay (Bio-Rad Laboratories). For gel shift assays, double-stranded oligonucleotide probes were end-labeled with [γ-P 32 PP]ATP using T4 polynucleotide kinase (New England Biolabs, Beverly, MA). Labeled probes were purified using ProbeQuant G-50 micro columns (Amersham Pharmacia Biotech, Piscataway, NJ). Binding reactions were conducted at room temperature for 20 min in a 20 μl total volume containing 0.5 ng of labeled probe, 5 μg of nuclear extract, 1 μg of poly(dI⋅dC) (Amersham Pharmacia Biotech) and gel shift buffer (12 mM HEPES, pH 7.9, 4 mM Tris-HCl, pH 7.9, 60 mM KCl, 5 mM MgClB 2 B , 5 mM dithiothreitol (DTT) and 12.5% glycerol). For competition assays, competing oligonucleotides were preincubated with the reaction mix at room temperature for 15 min before the addition of radiolabeled probe. Binding reactions were size-fractionated using a 5% non-denaturing PAGE in 0.5× TBE and electrophoresed at 120 V for 4 h at room temperature. The gel was subsequently transferred onto 3MM chromatography paper, dried and exposed to autoradiographic film for 1 to 3 days at −80°C. The probe sequences were: p154_105, 5′-TCA CCG GGT ACT TGC CAT GCA GGA GGC GCT GTG ATA GCT CTC CAA GTA GA-3′ and p154_130, 5′-TCA CCG GGT ACT TGC CAT GCA GGA G-3′. Competitor sequences were: p154_105, as above; p154_130, as above; p129_105, 5′-GCG CTG TGA TAG CTC TCC AAG TAG A-3′; p154_130_mut, 5′-TCA CCG GGT AU AG AU T P F 1 FP T GC CAT GCA GGA G-3′; NF-κB consensus, 5′-AGT TGA GGG GAC TTT CCC AGG C-3′; NFATc consensus, 5′-CGC CCA AAG AGG AAA ATT TGT TTC ATA-3′; Ets-1 consensus, 5′-GAT CTC GAG CAG GAA GTT CGA-3′; Elk-1 consensus, 5′-GGG CTG CTT GAG GAA GTA TAA GAA T-3′; Elf-1, 5′-CTT GGG GGC AGG ACT TCC TGT TTC T-3′ (30); CP2/LSF consensus, 5′-GTC TGA TTT CAC AGG AA-3′ (31); Sp1 consensus, 5′-ATT CGA TCG GGG CGG GGC GAG C-3′; AP1 consensus, 5′-CGC TTG ATG ACT CAG CCG GAA-3′.
RESULTS

ICOS induction by TCR and CD28 coengagement is subject to transcriptional control.
ICOS expression is induced upon T cell activation and in particular, in response to TCR and CD28 co-engagement (29) . To examine in detail the kinetics of ICOS induction, we first determined the level of ICOS cell surface expression and correlated that with the induction of ICOS mRNA in murine primary CD4P + P T cells stimulated with anti-CD3 and anti-CD28 antibodies, which engaged the TCR and CD28 respectively (henceforth designated as TCR/CD28). As shown in Fig. 1A , an increase in cell surface expression of ICOS could be detected as early as 6 h of T cell activation using a fluorochrome-conjugated anti-ICOS antibody in flow cytometry analysis, and the expression level seems to peak at 40 h of T cell stimulation. At the transcriptional level, an increase in ICOS mRNA could be detected via real-time RT-PCR as early as 3 h after TCR/CD28 stimulation and the mRNA level appeared to peak and plateau from 6 to 18 h before declining (Fig. 1B) . Thus, it was evident from the temporal increase in mRNA and cell surface protein expression that ICOS was subjected to some level of transcriptional control.
The underlined sequences denote the mutant binding site for Erk-sensitive TF(s).
ICOS expression is regulated by distinct pathways downstream of TCR and CD28 signaling.
Since TCR/CD28 stimulation could lead to an increase in ICOS mRNA and cell surface protein expression, we were interested to characterize the signaling pathways that regulate ICOS induction. To accomplish this, we first utilized a range of chemical inhibitors to block intracellular signaling pathways known to be activated by TCR/CD28 engagement in primary CD4P + P T cells and assessed their effects on cell surface ICOS induction ( Fig. 2A) . Our data shows that FK506 (tacrolimus), which is known to inhibit calcineurin, substantially diminished cell surface expression of ICOS on activated T cells, thus suggesting a possible role for this pathway in ICOS induction. This was consistent with a previous study that showed an inhibitory effect of CsA, which also deactivates calcineurin, on ICOS induction in human CD4P + P T cells (9) . Furthermore, as calcineurin is CaP In addition, we show that PP2 but not piceatannol also attenuated TCR/CD28-induced ICOS induction, hence implicating the Src rather than Syk family of protein tyrosine kinases in regulating ICOS expression ( Fig. 2A) . Again, the regulation of ICOS by the Src family kinases appeared to be at the transcriptional level as PP2-treated TCR/CD28-activated CD4P + P T cells had reduced levels of ICOS mRNA compared to control cells (Fig. 2B) . To ascertain which of the Src kinases were involved (Fyn and Lck being the most highly expressed in T cells), we treated cells with damnacanthal, a highly potent and selective inhibitor of Lck activity (32) . ICOS induction at both the cell surface protein and mRNA expression levels were unaltered by damnacanthal treatment, thus implicating Fyn but not Lck as the primary tyrosine kinase involved ( Figs. 2A and B 2C and D) .
TCR/CD28 engagement is also known to activate the various MAPKs (33) . We found that ERK, but not JNK or p38 MAPK, played a critical role in ICOS induction. ICOS induction was virtually abrogated when TCR/CD28-activated CD4P + P T cells were pre-treated with the ERK inhibitor, U0126, but not with the JNK inhibitor (L-form) or p38 inhibitor, SB203580 ( Fig. 2A, middle panel) .
This inhibition appeared to act also at the transcriptional level, similar to that mediated by CsA and PP2 (Fig.  2B) .
Despite a number of studies emphasizing the importance of phosphatidylinositol-3-kinase (PI-3K) in CD28 signaling leading to cell activation, proliferation and survival (34) (35) (36) , ICOS induction did not seem to be dependent on PI-3K or mTOR pathways because treatment of cells with wortmannin (WM) or rapamycin (RAPA) respectively, did not affect TCR/CD28-mediated ICOS upregulation ( Fig. 2A, right panel) . We also did not observe any effect of SN-50 inhibitor peptide on ICOS induction, thus indicating a negligible or redundant role for NF-κB in TCR/CD28-mediated ICOS induction.
As a control to ensure that the dampening of ICOS induction by some of the chemical inhibitors examined above was not due to their effect on the surface expression of CD3 and/or CD28 molecules leading to diminution of ICOS induction, we treated CD4P + P T cells with these inhibitors for 16 h and found that the cell surface expression of CD3 and that of CD28 were unaffected by these inhibitors (data not shown).
Finally, we also addressed the feasibility of using the mouse EL4 T cell line as a model for subsequent study of ICOS regulation. Although there was already a high level of basal ICOS transcript in EL4 cells, the level of ICOS mRNA in these cells could be further elevated upon TCR/CD28 or PMA and ionomycin (henceforth designated as P/I) stimulation (Fig. 2E and data 
Fyn induces ICOS transcription in part through NFATc2 independently of ERK
Since the above study with U0126 implicated ERK in TCR/CD28-mediated ICOS induction, we expressed a constitutively active form of MEK2 (caMEK2), which is the upstream kinase of ERK, in EL4 cells to determine if hyperactivation of ERK would result in enhanced ICOS induction. As shown in Fig. 3A , the expression of increasing amounts of caMEK2 resulted in a dosage-dependent induction of ICOS mRNA levels. This result, together with our previous data using U0126, unambiguously established a role for ERK in ICOS induction.
As we demonstrated earlier that the signaling pathways leading to TCR/CD28-mediated ICOS induction were sensitive to CsA and FK506 (Fig. 2) , we hypothesized that NFAT proteins could be involved in TCR/CD28-mediated ICOS induction. Three NFAT family members are expressed in T cells, namely, NFATc1, NFATc2 and NFATc3 (37) . As shown in Fig. 3A , over-expression of NFATc2 in P/I-treated EL4 cells led to a dramatic increase in ICOS mRNA levels whereas the level of ICOS mRNA induction was modest or negligible in P/I-treated EL4 cells respectively over-expressing NFATc1 or NFATc3. Thus, NFATc2 is involved in TCR/CD28-induced ICOS mRNA up-regulation.
The studies so far had indicated that Fyn, ERK, calcineurin and NFATc2 were involved in TCR/CD28-mediated ICOS induction. However, within the TCR/CD28 signal transduction hierarchy, the participation of Fyn and ERK is proximal with respect to the downstream transcription factor (TF) NFATc2. To determine if Fyn-or ERK-mediated ICOS induction occurs in part via NFATc2, we examined the effect of NFATc2 over-expression in TCR/CD28-stimulated EL4 cells pre-treated with PP2 or U0126 (Fig. 3C) . As expected, PP2 or U0126 treatment inhibited ICOS induction in TCR/CD28-stimulated EL4 cells. Interestingly, NFATc2 over-expression could overcome the dampening of ICOS induction in PP2-treated but not U0126-treated TCR/CD28-activated EL4 cells in a dose-dependent manner, suggesting that NFATc2 is probably downstream of Fyn but not ERK in inducing ICOS transcription.
NFATc2 resides in the cytoplasm and translocates to the nucleus upon activation (38) . Consistent with the above finding that NFATc2 is downstream of Fyn but not ERK signaling, we also found that PP2 but not U0126 pre-treatment of TCR/CD28-stimulated EL4 cells resulted in a reduction of NFATc2 translocation into the nucleus compared to untreated or U0126-treated cells that were subjected to the same stimulus (Fig. 4A) .
Although most studies of TCR signaling have positioned ERK downstream of Fyn in the TCR signalosome, our data seems to indicate that ERK acts in a signaling axis distinct from Fyn in regulating ICOS upon TCR/CD28 stimulation. To further clarify this, we examined ERK activation in the absence of Fyn signaling in EL4 cells. As shown in Fig. 4B , TCR/CD28-stimulated EL4 cells, with or without PP2 pretreatment, was comparable (Fig. 4B) 
A 288-bp core promoter region of icos confers PMA and ionomycin-induced expression of a reporter in vitro
To further elucidate the molecular mechanisms leading to icos promoter activation, we first tested a 1.48-kb KpnI−HindIII fragment 5′ of the transcription start site (TSS) of the mouse icos gene for possession of promoter activity. This fragment was linked in the sense orientation to the promoterless luciferase (Luc) reporter vector pGL3B to create mICOSp(−1478)-Luc, which was transiently cotransfected with a normalization vector, pRL-Renilla into EL4 cells. Subsequently, cells were left in medium alone or stimulated with P/I, and after a further 14 to 16 hours of incubation, harvested and evaluated for Luc activity. P/I were used instead of anti-CD3 and anti-CD28 antibodies for stimulating cells as the former treatment gave a larger fold increase in luciferase activity compared to the latter (data not shown).
As seen in Fig. 5A , the icos 5' 1.48-kb DNA fragment conferred significant Luc activity in stimulated EL4 cells.
There was an approximately 61-fold induction in Luc activity in cells stimulated with P/I compared to cells in medium only. As a control, insertion of the same promoter fragment in the antisense orientation resulted in a complete loss of its ability to activate the reporter construct (data not shown). Thus, the data indicates that the 1.48-kb region upstream of icos TSS contains significant promoter activity.
To define more specifically the elements contributing to icos promoter activity, we generated a series of promoter mutants by truncating the 1.48-kb DNA fragment from the 5′ end. While the 900-bp BglII−HindIII (−900 to −1) and the 599-bp XhoI−HindIII (−599 to −1) fragments retained promoter activity, additional deletion of the icos promoter revealed that a 288-bp fragment was the minimum region responsible for substantial transcriptional activating capability associated with the 1.48-kb parental fragment. A further 5′ truncation yielding a 147-bp fragment resulted in dramatic reduction of promoter activity (∼10-fold loss in Luc activity) and subsequent deletions leading to 109-bp and 52-bp fragments led to an almost complete loss of promoter activity (Fig. 5A) . Hence, based on these in vitro luciferase reporter assays, we concluded that the 288 bp region upstream of the icos TSS was the minimum DNA region that retained significant promoter activity capable of conferring high level of ICOS transcription.
Requirement of NFATc2 and ERK-dependent transcription factor(s) for icos core promoter activity
We next asked if Fyn-NFATc2 and ERK signaling cascades could influence the core promoter activity of icos. To this end, we assessed the effects of CsA and U0126 treatment on the promoter activity of the 288-bp, 147-bp and 109-bp DNA fragments of icos. We observed that CsA treatment reduced markedly the reporter activity of the 288-bp but not the 147-bp fragment following transient cotransfection of mICOSp(−288)-Luc, mICOSp(−147)-Luc or mICOSp(−109)-Luc and pRL-Renilla in EL4 cells (Fig. 5B, left panel) . In contrast, U0126 treatment virtually obliterated the promoter activities of both the 288-bp and 147-bp fragments, suggesting that ERK signaling has a very profound effect on the activation status and/or DNA binding activity of potential TFs that recognize the cis-regulatory elements within the 147-bp region (Fig. 5B, right  panel) . In addition, our data suggests that CsAsensitive TFs such as NFAT probably act within the region between 288 and 147 bp upstream of icos TSS.
To further support the findings that ERK and NFAT signaling are involved in the induction of ICOS transcription through specific action within the 288 bp promoter region, we over-expressed individually caMEK2 and NFATc2 in cells harboring mICOSp(−288)-Luc. Both caMEK2 and NFATc2 could enhance the promoter activity of mICOSp(−288)-Luc (Fig.  5C, left panel) . Strikingly, cotransfection of both led to a synergistic amplification of promoter activity, suggesting the possibility of cooperation between the ERK-responsive TFs and NFATc2 in accentuating icos promoter activity. Thus, ERK and NFATc2 could cooperatively activate the icos promoter. Furthermore, consistent with the data shown in Fig. 5B , over-expression of caMEK2 could also enhance the promoter activity of mICOSp(−147)-Luc (but not mICOSp(−109)-Luc) comparable to that of mICOSp(−288)-Luc, indicating that the ERK-responsive TFs act in this region of the promoter (Fig. 5C, right  panel) .
NFATc2 binds icos 288-bp core promoter in vivo and is affected by Fyn signaling
In order to delineate the cis-regulatory elements contributing to icos core promoter activity, we proceeded to search for putative TFbinding sites within the 288-bp region by employing the web-based software, MATINSPECTOR (H T U www.genomatix.deU T H ) and RVISTA 2.0 (H T U http://rvista.dcode.orgU T H ) (40, 41) , which are closely interconnected with the TRANSFAC database.
These programs predicted the presence of potential AP1, C/EBPβ and Ikaros but surprisingly, not NFATc binding sites, even though we showed an important role for NFATc2 in activating the icos promoter. From the algorithmic predictions, we postulated that AP1 could be another TF candidate that regulates ICOS expression as c-fos was directly downstream of ERK in many signaling pathways. However, preliminary experiments exploring site-directed mutagenesis of the putative AP1 site (and other sites) within mICOSp(−288)-Luc did not lead to reproducible reduction in Luc reporter activity. Conversely, over-expression of c-fos did not further enhance Luc activity in EL4 cells cotransfected with mICOSp(−288)-Luc (data not shown).
Since NFATc2 over-expression resulted in increased mICOSp(−288)-Luc activity (Fig.  5C, left panel) , we asked if NFATc2 could bind the 288-bp fragment in vivo. Using ChIP assays, we detected a basal level of constitutive binding of NFATc2 to the icos promoter in resting EL4 cells (Fig. 6A, upper panel, lane 5) , possibly as a result of deregulated CaP 2+ P signaling in these cells (42) . Importantly, this level of binding was substantially increased when EL4 cells were stimulated with anti-CD3 and anti-CD28 antibodies (lane 6). PP2 treatment on similarly stimulated cells resulted in a reduction in NFATc2 binding (lane 7), suggesting that the positive impact of Fyn signaling on ICOS transcription observed earlier is via enhancing NFATc2 binding of the icos 288-bp promoter. As a positive control, CsA treatment was also observed to diminish, though not to the same extent, NFATc2 binding (lane 8). Binding of NFATc2 to the icos promoter was specific as ChIP performed using an isotype-matched antibody did not produce visible PCR products (lanes 1 -4) . We also examined the binding of NFATc2 to the icos promoter in primary CD4P + P T cells lacking Fyn (Fig. 6B) . Consistent with the finding that Fyn and NFATc2 act in the same signaling axis to activate ICOS transcription, we show that there was reduced binding of NFATc2 to the icos promoter in Fyn-deficient CD4P 
Identification of an ERK-responsive site in the icos promoter
Since treatment with U0126 affected ICOS induction in TCR/CD28-stimulated T cells and this effect appeared to be at the promoter level, we sought to identify potential ERKresponsive site(s) within the icos core promoter region. To this end, we designed a set of double-stranded oligonucleotides which overlapped each other and spanned the region 154 bp to 105 bp upstream of the icos TSS and used them to compete against nuclear extract binding by this region. As shown in Fig 7A, Moreover, introduction of a 3-bp mutation corresponding to 144 bp to 142 bp of p154_130 (p154_p130_mut) interfered largely with the ability of unlabelled p154_130_mut to compete with the radiolabelled p154_130 (Fig. 7A, right panel, lane 4) , suggesting that the integrity of this site is important to facilitate optimal binding of as yet undetermined nuclear protein factors. EMSA assays revealed that there was considerable induction of complex binding of the stated region to nuclear extracts obtained from either P/I-stimulated EL4 cells or TCR/CD28-activated murine primary CD4P + P T cells compared to those of resting cells (Fig. 7B,  lanes 2 and 5 respectively) . This binding was reduced dramatically or abrogated in activated EL4 and CD4P + P T cells pre-treated with U0126 (respectively lanes3 and 6).
To definitively confirm the functional relevance of the region spanning 154 bp to 130 bp upstream of the icos TSS in responding to ERK signaling, we replicated the above described mutation spanning 144 bp to 142 bp in the mICOSp(−288)-Luc construct to yield mICOSp(−288)-ERK-mut-Luc and assessed the latter's reporter activity in EL4 cells ectopically expressing constitutively active MEK2. Consistent with our previous result demonstrating compromised nuclear complex binding, the introduced mutation in mICOSp(−288)-Luc led accordingly to a drastic reduction in Luc activity (Fig. 7C, left panel) .
Interestingly, a drastic attenuation in Luc activity was also observed in EL4 cells over-expressing NFATc2 (Fig. 7C, right panel) , alluding to a possible functional hierarchy involving ERKsensitive TFs and NFATc2 whereby the latter critically requires the former to operate, otherwise its own function is crippled. In other words, ERK signaling appeared to be extremely important in initiating or sustaining basal ICOS transcription, whereas NFATc2 as well as other possible TFs played a more ancillary role in amplifying transcription.
This finding is consistent with the failure of exogenous NFATc2 to rescue ICOS transcription in U0126-treated EL4 cells (Fig. 3C ) and the earlier purported cooperativity of ERK and NFATc2 signaling (Fig. 5C, left panel) .
Since the region spanning 154 bp to 130 bp was responsive to ERK signaling, we attempted to identify the TF(s) that binds this region. For this purpose, we designed a series of unlabelled oligonucleotides bearing consensus DNA sequences that were known and had been shown to bind various ERK-sensitive TFs such as Ets-1, Elf-1, Elk-1, CP2 or LSF, Sp1 and AP-1 as well as those recognizing NFATc and NF-κB, and used these to compete with the binding of nuclear extracts from activated EL4 or CD4P + P T cells to the icos promoter. None of these unlabelled oligonucleotides convincingly competed with the radiolabelled p154_130 in binding the protein complex from activated EL4 or CD4P + P T cells (Fig. 7D) . Furthermore, the DNA-protein complex did not supershift with either anti-c-fos or anti-c-jun Abs (data not shown). Thus, at this juncture, we are unable to ascertain the identity of the TF(s), except to report that it was responsive to ERK.
DISCUSSION
ICOS is a member of the CD28 superfamily of costimulatory receptors that is expressed at low levels on naïve T cells but rapidly upregulated on activated T cells. Although the in vivo functions of ICOS in health and disease is quite well understood, very little is known about the molecular mechanisms that regulate ICOS expression. In this study, we present evidence that the Fyn-calcineurin-NFATc2 and MEK2-ERK1/2 signaling pathways directly induce ICOS expression upon TCR and CD28 costimulation of T cells.
We first demonstrated that there was a direct correlation between the up-regulation of ICOS cell surface expression and the induction of its mRNA, suggesting that TCR/CD28 signaling directly regulate ICOS expression at the transcriptional level. Both TCR and CD28 stimulation are known to activate a number of downstream signaling molecules, and it is expected that not all of them are involved in regulating ICOS. T cells possess both the Syk and Src family of tyrosine kinases, which are important in proximal TCR signaling. Our data indicate that Src family tyrosine kinases play a major role in TCR-mediated ICOS induction. Of the two major Src kinases present in T cells, namely Lck and Fyn, the latter seems to be critical for inducing ICOS. This demonstrates a non-redundancy of the two kinases in an important aspect of T cell physiology.
Consistent with the fact that CD28 costimulation is known to activate the NFAT family of transcription factors, our results clearly demonstrate an important role for NFATc2 in activating ICOS transcription (Figs. 3, 5 and 6 ). TCR engagement is known to activate the CaP 2+ P/calmodulin-dependent serine phosphatase, calcineurin, which dephosphorylates NFAT proteins and leads to their translocation into the nucleus. Nuclear NFAT has been shown to activate cytokine gene (e.g. IL-2) promoters and enhancers, resulting in positive T cell responses (reviewed in Refs. (43, 44) ). Our studies expand these previous findings and implicate an additional nontrivial role for the calcineurinNFATc2 pathway in up-regulating ICOS transcription. This was supported by our data showing the ability of the immunosuppressive drug CsA in blocking ICOS induction at both the cell surface receptor and mRNA levels ( Fig. 2A,  B and E) and affecting icos promoter activity (Fig. 5B, left panel) . Moreover, exogenously expressed NFATc2 could enhance ICOS mRNA levels (Fig. 3B ) and promoter activity (Fig. 5C,  left panel) . Thus, NFATc2 is involved in the regulating ICOS expression.
The attenuation of NFATc2 nuclear translocation and in vivo occupation of the icos promoter region following PP2 treatment of activated T cells and the ability of NFATc2 over-expression to overcome PP2 inhibition of ICOS induction in activated EL4 cells places NFATc2 downstream of Fyn in the signaling axis that induces ICOS expression. Indeed, evidence that the binding of icos promoter by NFATc2 is compromised in FynP Other major pathways activated by TCR and CD28 signaling include those involving MAPKs, of which ERK appeared to play a major role in ICOS induction. This is inferred from the efficiency of the pharmacological inhibitor U0126 (but not p38 inhibitor SB203580 or JNK inhibitor I) to block ICOS receptor ( Fig. 2A) and mRNA ( Fig. 2B and E) up-regulation, as well as almost ablating icos promoter activity (Fig. 5B,  right panel) . Cotransfection assays with a constitutively active form of MEK2 (caMEK2) demonstrated that over-expressed caMEK2 enhanced ICOS transcription (Fig. 3A) and promoter activity (Fig. 5C ). Although we eventually identified a functional target site residing within 148 to 136 bp of the icos promoter region responsive to ERK signaling (because mutation of this site severely dampened reporter activity in caMEK2-over-expressed EL4 cells (Fig. 7D) ), it is far from clear what the identity of the TF(s) that binds this region is. Further investigation has to be carried out to determine the identity of this TF(s).
Our current findings also seem to suggest that ERK signaling independently and critically regulate ICOS expression as the overexpression of NFATc2 could not rescue the U0126-mediated block in ICOS induction (Fig.  3C) . Intriguingly, the ERK-responsive TF(s) appeared to occupy an icos promoter region that is different from that recognized by NFATc2. The over-expression of NFATc2 and caMEK2 synergistically induce ICOS expression at the mRNA level. Finally, mutation of the ERKsensitive site within the icos promoter not only significantly impaired the ability of ERK but also NFATc2 in driving high levels of ICOS transcription. These data collectively support a model of two signaling pathways, namely Fyncalcineurin-NFATc2 and MEK2-ERK1/2, that independently converge on the icos promoter to regulate transcription, with the added complexity that while ERK signaling is critical in initiating ICOS transcription, NFATc2 augments this ERK-mediated signal.
The study of the transcriptional regulation of ICOS is of immense importance due as the human chromosome region 2q33 that harbors the costimulatory cluster of CD28, ICOS and CTLA-4 genes has been linked to a number of autoimmune diseases. Sequence alignment of regions flanking the first coding exon of the mouse and human icos genomic DNA revealed two zones of sequence homology separated by a ∼250-bp mouse-specific repetitive DNA region (45). Interestingly, we found that the 288-bp region defined in this report to possess promoter activity is located within the mouse-specific repetitive region, implying possible differences in the regulation of mouse as compared to human ICOS transcription. Indeed, while ICOS plays an important role in the development of and is preferentially expressed in mouse Th2 cells (46, 47) , its expression appears to be enhanced in human Th1 cells (48), although a recent study determined that polymorphisms in the human ICOS promoter are significantly associated with allergic sensitization and Th2 cytokine production (49). Thus, it is conceivable that differences in ICOS expression, brought about by differences in its transcriptional regulation, could influence immune responses in allergic, autoimmune and disease conditions.
Because ICOS plays an important role in the pathogenesis of many diseases, understanding the molecular mechanisms by which ICOS is regulated may present new opportunities for therapeutic intervention of pathologies involving this costimulatory molecule. In this regard, our current studies could shed light on human studies investigating the association of autoimmune diseases such as multiple sclerosis and type I diabetes with polymorphisms in the CD28/CTLA4/ICOS gene cluster.
In summary, this work has defined two molecular pathways downstream of TCR and CD28 signaling, namely Fyn-calcineurinNFATc2 and MEK2-ERK1/2, in the regulation of mouse ICOS transcription (Fig. 8) . Furthermore, we demonstrated the binding of ICOS promoter by NFATc2 and delineated an ERK-responsive site in the promoter which likely binds yet-to-be-identified TF(s). Future work will center on discovering other possible signaling pathways and TFs that regulate ICOS expression, especially those signaling pathways associated with the polarization of T cells into different T cell subsets. 
